{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:59:54Z","timestamp":1789588794946,"version":"build-2803163510"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T00:00:00Z","timestamp":1579824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0228162","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T18:31:23Z","timestamp":1579890683000},"page":"e0228162","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of liposomal ciprofloxacin formulations in a murine model of anthrax"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2271-7331","authenticated-orcid":true,"given":"Chad W.","family":"Stratilo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Crichton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,1,24]]},"reference":[{"issue":"3","key":"pone.0228162.ref001","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/08998280.2005.11928074","article-title":"Anthrax: a continuing concern in the era of bioterrorism","volume":"18","author":"S Riedel","year":"2005","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"18","key":"pone.0228162.ref002","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.281.18.1735","article-title":"Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense","volume":"281","author":"TV Inglesby","year":"1999","journal-title":"JAMA"},{"issue":"2","key":"pone.0228162.ref003","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.annemergmed.2005.11.035","article-title":"Anthrax: a systematic review of atypical presentations","volume":"48","author":"JE Holty","year":"2006","journal-title":"Ann Emerg Med"},{"issue":"9","key":"pone.0228162.ref004","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0966-842X(02)02422-8","article-title":"The alveolar macrophage: the Trojan horse of Bacillus anthracis","volume":"10","author":"C Guidi-Rontani","year":"2002","journal-title":"Trends Microbiol"},{"issue":"12","key":"pone.0228162.ref005","doi-asserted-by":"crossref","first-page":"7994","DOI":"10.4049\/jimmunol.178.12.7994","article-title":"Lung dendritic cells rapidly mediate anthrax spore entry through the pulmonary route","volume":"178","author":"A Cleret","year":"2007","journal-title":"J Immunol"},{"issue":"11","key":"pone.0228162.ref006","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJM199909093411107","article-title":"Anthrax","volume":"341","author":"TC Dixon","year":"1999","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0228162.ref007","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1462-5822.2000.00067.x","article-title":"Early Bacillus anthracis-macrophage interactions: intracellular survival survival and escape","volume":"2","author":"TC Dixon","year":"2000","journal-title":"Cell Microbiol"},{"issue":"5","key":"pone.0228162.ref008","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1128\/IAI.06061-11","article-title":"Updating perspectives on the initiation of Bacillus anthracis growth and dissemination through its host","volume":"80","author":"ZP Weiner","year":"2012","journal-title":"Infect Immun"},{"issue":"10","key":"pone.0228162.ref009","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.micinf.2016.06.004","article-title":"Bacillus anthracis spore movement does not require a carrier cell and is not affected by lethal toxin in human lung models","volume":"18","author":"JL Booth","year":"2016","journal-title":"Microbes Infect"},{"issue":"6","key":"pone.0228162.ref010","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3201\/eid0706.010604","article-title":"Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States","volume":"7","author":"JA Jernigan","year":"2001","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"pone.0228162.ref011","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1128\/AAC.00820-09","article-title":"Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model","volume":"54","author":"HS Heine","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0228162.ref012","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2174\/1874285801004010034","article-title":"Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis","volume":"4","author":"JW Peterson","year":"2010","journal-title":"The open microbiology journal"},{"issue":"4","key":"pone.0228162.ref013","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1128\/AAC.01689-10","article-title":"Antibiotics cure anthrax in animal models","volume":"55","author":"S Weiss","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"20","key":"pone.0228162.ref014","doi-asserted-by":"crossref","first-page":"7813","DOI":"10.1073\/pnas.0602748103","article-title":"Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax","volume":"103","author":"NJ Vietri","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"pone.0228162.ref015","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.1128\/AAC.01376-15","article-title":"Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits","volume":"59","author":"S Weiss","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"pone.0228162.ref016","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa0810603","article-title":"Raxibacumab for the treatment of inhalational anthrax","volume":"361","author":"TS Migone","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0228162.ref017","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/toxins5010120","article-title":"Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin\/ raxibacumab-treated New Zealand white rabbits","volume":"5","author":"A Corey","year":"2013","journal-title":"Toxins"},{"issue":"2","key":"pone.0228162.ref018","doi-asserted-by":"crossref","DOI":"10.3201\/eid2002.130687","article-title":"Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults","volume":"20","author":"KA Hendricks","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"pone.0228162.ref019","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1517\/17425247.3.1.71","article-title":"Aerosolised antibiotics: a critical appraisal of their use","volume":"3","author":"JK Hagerman","year":"2006","journal-title":"Expert opinion on drug delivery"},{"key":"pone.0228162.ref020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2014.11.004","article-title":"Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead","volume":"85","author":"T Velkov","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"pone.0228162.ref021","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijantimicag.2014.10.008","article-title":"Inhaled antibiotics beyond aminoglycosides, polymyxins and aztreonam: A systematic review","volume":"45","author":"ME Falagas","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"pone.0228162.ref022","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00003495-200767060-00006","article-title":"Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia","volume":"67","author":"GC Wood","year":"2007","journal-title":"Drugs"},{"issue":"1","key":"pone.0228162.ref023","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics8010006","article-title":"Development of Liposomal Ciprofloxacin to Treat Lung Infections","volume":"8","author":"D Cipolla","year":"2016","journal-title":"Pharmaceutics"},{"issue":"9","key":"pone.0228162.ref024","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial","volume":"68","author":"DJ Serisier","year":"2013","journal-title":"Thorax"},{"issue":"5","key":"pone.0228162.ref025","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1358\/dot.2012.48.5.1789474","article-title":"Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin","volume":"48","author":"DJ Serisier","year":"2012","journal-title":"Drugs Today (Barc)"},{"key":"pone.0228162.ref026","article-title":"Safety, Tolerability and Pharmacokinetics of Novel Liposomal Ciprofloxacin formulations for inhalation in Healthy volunteers and Non-Cystic bronchiectasis Patients","volume":"181","author":"P Bruinenberg","year":"2010","journal-title":"Am J Resp Crit Care"},{"key":"pone.0228162.ref027","article-title":"Safety, Tolerability, Pharmacokinetics & Antimicrobial Activity of Inhaled Liposomal Ciprofloxacin Formulations in Humans","volume":"354","author":"P Bruinenberg","year":"2010","journal-title":"Pediatr Pulm"},{"key":"pone.0228162.ref028","article-title":"Inhaled Liposomal Ciprofloxacin In Patients With Bronchiectasis And Chronic Pseudomonas AerugINOSa Infection: Results From Two Parallel Phase Iii Trials (orbit-3 And-4)","volume":"195","author":"C Haworth","year":"2017","journal-title":"Am J Resp Crit Care"},{"key":"pone.0228162.ref029","article-title":"Inhaled Liposomal Ciprofloxacin Hydrochloride Significantly Reduces Sputum Pseudomonas Aeruginosa Density in CF and Non-CF Bronchiectasis","volume":"179","author":"D Bilton","year":"2009","journal-title":"Am J Resp Crit Care"},{"issue":"10","key":"pone.0228162.ref030","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1080\/03639040801958421","article-title":"Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects","volume":"34","author":"S Chono","year":"2008","journal-title":"Drug development and industrial pharmacy"},{"issue":"11","key":"pone.0228162.ref031","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1128\/AAC.37.11.2293","article-title":"Liposome-incorporated ciprofloxacin in treatment of murine salmonellosis","volume":"37","author":"M Magallanes","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0228162.ref032","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1128\/AAC.42.1.45","article-title":"Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation","volume":"42","author":"MS Webb","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"pone.0228162.ref033","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00440-18","article-title":"Effective Treatment of Mycobacterium avium subsp. hominissuis and Mycobacterium abscessus Species Infections in Macrophages, Biofilm, and Mice by Using Liposomal Ciprofloxacin","volume":"62","author":"JD Blanchard","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0228162.ref034","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fcimb.2014.00079","article-title":"The potential of liposome-encapsulated ciprofloxacin as a tularemia therapy","volume":"4","author":"KA Hamblin","year":"2014","journal-title":"Frontiers in cellular and infection microbiology"},{"issue":"9","key":"pone.0228162.ref035","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1128\/AAC.03443-14","article-title":"Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever","volume":"58","author":"IH Norville","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"pone.0228162.ref036","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1128\/AAC.02555-13","article-title":"Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4","volume":"58","author":"KA Hamblin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0228162.ref037","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fmicb.2017.00091","article-title":"Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague","volume":"8","author":"KA Hamblin","year":"2017","journal-title":"Frontiers in microbiology"},{"issue":"10","key":"pone.0228162.ref038","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1016\/S0021-9258(18)62213-6","article-title":"The stability of messenger ribonucleic acid during sporulation in Bacillus subtilis","volume":"246","author":"TJ Leighton","year":"1971","journal-title":"J Biol Chem"},{"issue":"4","key":"pone.0228162.ref039","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1128\/AEM.35.4.762-765.1978","article-title":"Use of ethanol for selective isolation of sporeforming microorganisms","volume":"35","author":"JR Koransky","year":"1978","journal-title":"Appl Environ Microbiol"},{"issue":"8","key":"pone.0228162.ref040","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1128\/IAI.72.8.4801-4809.2004","article-title":"Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility","volume":"72","author":"CR Lyons","year":"2004","journal-title":"Infect Immun"},{"issue":"41","key":"pone.0228162.ref041","doi-asserted-by":"crossref","first-page":"6740","DOI":"10.1016\/j.vaccine.2010.07.075","article-title":"An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor","volume":"28","author":"LW Baillie","year":"2010","journal-title":"Vaccine"},{"issue":"6","key":"pone.0228162.ref042","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1128\/IAI.01875-06","article-title":"Murine aerosol challenge model of anthrax","volume":"75","author":"CL Loving","year":"2007","journal-title":"Infect Immun"},{"issue":"6","key":"pone.0228162.ref043","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1128\/AAC.41.6.1288","article-title":"Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice","volume":"41","author":"J Conley","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pone.0228162.ref044","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0168-3659(03)00358-4","article-title":"Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection","volume":"92","author":"JP Wong","year":"2003","journal-title":"Journal of controlled release: official journal of the Controlled Release Society"},{"issue":"5","key":"pone.0228162.ref045","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1128\/AAC.36.5.993","article-title":"Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses","volume":"36","author":"JT Lettieri","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"pone.0228162.ref046","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1128\/AAC.01050-06","article-title":"Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model","volume":"51","author":"HS Heine","year":"2007","journal-title":"Antimicrob Agents Chemother"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0228162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T21:39:18Z","timestamp":1614116358000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0228162"}},"subtitle":[],"editor":[{"given":"Nupur","family":"Gangopadhyay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,24]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0228162","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,24]]}}}